BioAlliance launches Loramyc in France

France-based specialty pharmaceutical firm BioAlliance Pharma has launched its first drug, Loramyc, on the French market.

BioAlliance says it is the first biotech company in France to have successfully managed the whole process of bringing an academic innovation out of the lab, through r&d and onto the market.

Loramyc is available on the French market as of 4 September at pharmacies and healthcare establishments, following the official publication of its approval for use in hospitals as well as details of reimbursement by French health authorities.

The drug is specifically developed to treat Oropharyngeal Candidiasis in immunodepressed patients, who frequently suffer an associated mucositis. It offers an optimised anti-fungal treatment with the same level of activity as systemic therapies, with the advantage that it specifically targets the mouth and the oropharynx.

The new therapeutic approach uses an innovative delivery system based on a mucoadhesive buccal tablet. This ensures an early and extended release of the active component at the site of the infection, with only one dose per day.

"Our team of scientific sales representatives report that hospital oncology and infection specialists have shown a lot of interest in Loramyc, which responds to an unmet medical need," said Florence Dupre, vice president of sales & marketing at BioAlliance Pharma.